Merge Gains Visibility on RW Baird Comments
Long Ideas - Comments from RW Baird Friday morning point to Merge Healthcare (NASDAQ:MRGE) as a strong stock with near-term value drivers and potential as a take-out candidate. … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
SciClone Reportedly Exploring Strategic Options
Long Ideas - SciClone Pharmaceuticals (NASDAQ:SCLN) started the day strong, as the company is being cited by dealReporter as exploring strategic options. According to sources, the publication is noting … Continue Reading
Read nowPrice Targets To Rise On HALO As SC Cinryze Is Back On Track
Long Ideas - Halozyme Therapeutics (NASDAQ:HALO) and ViroPharma (NASDAQ:VPHM) announced this morning that the FDA is enabling their subcutaneous version (SC) of Cinryze, a treatment for hereditary angioedema … Continue Reading
Read nowVivus Expects Negative Decision on Qsiva from the EMA
Quick Picks - By Jake King Vivus Inc. (NASDAQ:VVUS) announced Friday morning that, based on preliminary communication with European regulators, the company doubts it will receive approval of … Continue Reading
Read nowPatent Licensure Positive, Removes Barrier To Potential SGYP Pharma Partnership
Long Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) released in an 8-k Thursday night that it has entered into an agreement with Ironwood Pharmaceuticals (NASDAQ:IRWD) for an exclusive worldwide license … Continue Reading
Read nowIdenix Presentation Does Little to Assuage Investors’ Fears
Long Ideas - A presentation from Idenix Pharmaceuticals (NASDAQ:IDIX) at the UBS Global Life Sciences conference Thursday did little to settle the nerves of IDIX investors who have … Continue Reading
Read nowNet Positive After QCOR Conference Call; Co. Continues To See Acthar Script Approvals
Research - The 48% decline seen for shares of Questcor Pharmaceuticals (NASDAQ:QCOR) Wednesday prompts the key question of: What to do with the stock now? As a … Continue Reading
Read now